Astral Foods Ltd. (ARL)
Johannesburg Stock Exchange · South Africa · prices in ZAC · close of 27 Oct 2026
Key indicators
| Last close | ZAC 21,000.00 |
|---|---|
| 52-week range | 17,422.00 – 28,390.00 |
| Return, 1 month / 3 months | +12.1% / +2.9% |
| Return, 1 year / 3 years | −4.7% / +46.5% |
| Trend | Below its 200-day average |
| RSI (14) | 65 |
| Volatility (1 year) | 24.6% |
| Worst drawdown (1 year) | -35.3% |
| Average daily value traded | 2,797.06M ZAC |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Astral Foods is a South African poultry and animal feed company based in Centurion. It produces broiler feed and day-old chicks, raises and processes chickens, and sells fresh and frozen chicken products to retailers, wholesalers and food service customers. Its operations span feed milling, breeding, hatching, farming and processing, and its branded chicken products are sold in supermarkets and outlets across southern Africa.
Astral Foods Ltd. trades under the code ARL on the Johannesburg Stock Exchange in South Africa, with its price quoted in South African cents (ZAC). Our dividend records, which start in 2019, show payments in 5 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Astral Foods Ltd. (ARL) trades on the Johannesburg Stock Exchange in South Africa. It last closed at ZAC 21,000.00 on 27 October 2026.
Its price-based Market X-Ray is 43 out of 100 (a weak price profile), ranking 154 of 238 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 4.7% and over the last three months it rose 2.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Johannesburg Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 22 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -10.0% | ||
| From 52-week high | -25.4% | ||
| Momentum | 35 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | 2.9% | ||
| 6-month return | -13.2% | ||
| 12-month return, skipping the last month | -14.9% | ||
| Stability (higher is calmer) | 57 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 24.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -35.3% | ||
| Liquidity | 67 · Fair | Moderate trading activity. | |
| Average daily value traded | 2,797.06M ZAC | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 2 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | +1.1% |
|---|---|
| 1 month | +12.1% |
| 3 months | +2.9% |
| 6 months | −13.2% |
| 1 year | −4.7% |
| 3 years | +46.5% |
| 5 years | +30.7% |
Signals
| 50-day / 200-day average | 19,648.28 / 23,333.69 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 673.00 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 11 Jan 2023 | ZAC 590.0000 |
| 8 Jun 2022 | ZAC 790.0000 |
| 12 Jan 2022 | ZAC 400.0000 |
| 9 Jun 2021 | ZAC 300.0000 |
| 13 Jan 2021 | ZAC 775.0000 |
| 15 Jan 2020 | ZAC 425.0000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Johannesburg Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.